| Literature DB >> 34932132 |
Marcel Opitz1, Georgios Alatzides2, Sebastian Zensen2, Denise Bos2, Axel Wetter2,3, Nika Guberina4, Marvin Darkwah Oppong5, Karsten H Wrede5, Tim Hagenacker6, Yan Li2, Isabel Wanke2,7, Michael Forsting2, Cornelius Deuschl2.
Abstract
PURPOSE: The aim of this study was to determine local diagnostic reference levels (DRLs) during endovascular diagnostics and therapy of carotid-cavernous fistulas (CCF).Entities:
Keywords: Carotid-cavernous fistula; Cerebral angiography; Embolization; Interventional neuroradiology; Radiation exposure
Mesh:
Year: 2021 PMID: 34932132 PMCID: PMC8894175 DOI: 10.1007/s00062-021-01126-x
Source DB: PubMed Journal: Clin Neuroradiol ISSN: 1869-1439 Impact factor: 3.649
Classification of the study population with carotid-cavernous fistula (CCF) according to the Barrow-classification
| Type | Shunt pattern | |
|---|---|---|
| A | Direct connection between the intracavernous internal carotid artery and cavernous sinus | 14 (29.2) |
| B | Dural shunt between intracavernous branches of the internal carotid and cavernous sinus | 8 (16.7) |
| C | Dural shunts between meningeal branches of the external carotid artery and cavernous sinus | 3 (6.2) |
| D | Combined type B + type C | 23 (47.9) |
Demographic data and distribution of procedure type
| Parameter | |
|---|---|
| 48 (100) | |
| 14 (29)/34 (71) | |
| 26 (54) | |
| 60 (100) | |
| With Onyx | 7 (12) |
| With coils | 23 (38) |
| With Onyx and coils | 20 (33) |
| Additional balloon protection of internal carotid artery | 9 (15) |
| Frustrated | 10 (17) |
| Transarterial | 12 (20) |
| Transvenous | 48 (80) |
Distribution of total dose area product and fluoroscopic time of carotid-cavernous fistula as a function of procedure type
| Type of procedure | Total DAP (Gy ∙ cm2) | FT (min) | ||||
|---|---|---|---|---|---|---|
| 25th percentile | Median | 75th percentile | Mean | Mean | ||
| Diagnostic | 26 | 101.17 | 168.61 | 214.68 | 164.83 | 18.67 |
| Embolization | 60 | 155.72 | 225.68 | 349.51 | 265.84 | 61.90 |
DAP dose area product, FT fluoroscopic time, n number of studies
Fig. 1Histograms of distribution of dose area product (Gy ∙ cm2) for embolization (upper) and diagnostic cerebral angiography (lower) in patients with CCF; blue curve highlighting distribution graph